Remetinostat Gel Promising for Basal Cell Carcinoma

FRIDAY, Aug. 6, 2021 -- The histone deacetylase (HDAC) inhibitor remetinostat may be effective for reducing the disease burden of basal cell carcinoma (BCC), according to a study published online Aug. 6 in Clinical Cancer Research. James M....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news